Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.

Comparison scale
Pfizer says abrocitinib performed better than Dupixent in a Phase III trial • Source: Alamy

Pfizer Inc.'s oral JAK1 inhibitor abrocitinib outperformed Sanofi/Regeneron Pharmaceuticals, Inc.'s blockbuster Dupixent (dupilumab) on efficacy in a head-to-head trial in atopic dermatitis, Pfizer reported on 30 August. The data are the first from a head-to-head trial comparing the two products, which work through different mechanisms of action.

Abrocitinib, which is under review at the US Food and Drug Administration, could be a new competitor in the therapeutic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last

 

The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By 

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.